Member Info for chriszzr

Well that tortoise is certainly making good progress!

Not sure how this works bet three identical trades in a short period of time

25-Jun-21 12:24:35 22.00 142,293 Buy* 21.00 22.50 31.30k O
25-Jun-21 12:25:14 22.0744 13,536 Buy* 21.00 22.50 2,988 O
25-Jun-21 12:24:26 22.00 142,293 Buy* 21.00 22.50 31.30k O
25-Jun-21 12:24:26 21.77777 18,410 Buy* 21.00 22.50 4,009 O
25-Jun-21 12:23:07 22.00 142,293 Buy* 21.00 22.50 31.30k O

Can a tortoise swim?

More progress on cancer detection via blood tests

NHS trials 'holy grail' blood test that can spot 50 kinds of cancer: Ground-breaking check that can accurately detect two thirds of deadly cancers early in healthy people could save thousands of lives a year
Blood test can detect two thirds of deadly cancers before someone finds a lump
Galleri test to be trialled by the NHS from the autumn, results expected in 2023
Test can pick up more than 50 cancers, described as the 'holy grail' for cancer
By VICTORIA ALLEN SCIENCE CORRESPONDENT FOR THE DAILY MAIL

PUBLISHED: 00:00, 25 June 2021 | UPDATED: 00:26, 25 June 2021

e-mail
24

View comments
A ground-breaking blood test set to be trialled by the NHS this autumn can accurately detect two thirds of deadly cancers.

The Galleri test, described as the ‘holy grail’ for cancer, detects the disease early in healthy people and NHS officials believe it has the potential to save thousands of lives every year.

Even before someone finds a lump, develops symptoms or visits their GP, early-stage cancerous cells can shed DNA into the bloodstream – which the blood test picks up.

Read More

Now results from 4,077 patients in the US show it can detect 67.6 per cent of 12 deadly cancers, including bowel, ovarian, lung and pancreatic.

The Galleri test, described as the ¿holy grail¿ for cancer, detects the disease early in healthy people and NHS officials believe it has the potential to save thousands of lives every year (stock image) +2
The Galleri test, described as the ‘holy grail’ for cancer, detects the disease early in healthy people and NHS officials believe it has the potential to save thousands of lives every year (stock image)

Overall, it can pick up more than 50 types of cancer. The results come as the NHS prepares to roll out the test to 140,000 people aged 50 to 77 with no cancer symptoms. Another 6,000 with suspected symptoms will be offered tests to speed up their diagnosis.

Each test, together with laboratory analysis which produces a result in around ten working days, costs $949, or around £620, in the US.

It is not known how much the NHS has paid for its pilot. The results are expected in 2023 and, if successful, the test will be made available to around a million people in 2024 and 2025.

The latest results, published in the journal Annals of Oncology, come from trials on 2,823 people with cancer and 1,254 who were cancer-free.

The test wrongly diagnosed people less than 1 per cent of the time – for just six people. For pancreatic cancer, one of the biggest killers because it is usually caught late, the test detected the disease 86.6 per cent of the time.

RELATED ARTICLES
Previous
1
2
Next

NHS cancer treatment backlog fueled by Covid pandemic 'can...

How statins could cut risk of cancer in heart patients:...

Family reveal the devastating effects of Covid on their...
SHARE THIS ARTICLE
Share
For more than 50 cancers, it detected them

Interesting start to the final day before the AGM

25/06/21 08:26 256,512 19.99 19.00 20.50 £51,276.75 Buy
25/06/21 08:04 253,870 19.69 19.00 20.00 £49,987.00 Buy
25/06/21 08:05 253,176 19.74 19.00 20.00 £49,976.94 Buy
25/06/21 08:04 101,281 19.74 19.00 20.00 £19,992.87 Buy

Or will it?

The UK government has given £3bn to a company selling covid tests the US government has recalled as not fit for use - and its solution is to say we should use more of them! Full story in the new Private Eye, in shops today.

Lateral flow test approval process must be reformed, industry leaders say
British companies that make the tests face difficulties winning approval through Public Health England’s process at Porton Down

By
Julia Bradshaw
23 June 2021 • 11:37am
Leaders from the diagnostics testing industry have called for greater transparency of the evaluation procedure for lateral flow tests, arguing that the existing framework is biased, dangerous and not fit for purpose.

Britain is heavily dependent on fast-acting lateral flow tests made in China by US private-equity backed company Innova. The Government has spent billions buying these tests, but their performance has been questioned by many in the scientific community.

The test was dealt a blow earlier this month when the US Food and Drug Administration issued a warning letter to Innova, saying it should be "thrown in the trash".

Meanwhile, UK-based and other diagnostics players with tests that exceed even World Health Organization standards have failed to win approval through Public Health England’s (PHE) evaluation process at Porton Down.

ADVERTISING

David Evans, a well-respected figure who has worked in the diagnostics industry for 28 years in senior positions, said the FDA’s warning letter to Innova had “profound implications in the UK for the confidence and integrity the public can place in any diagnostic test and the MHRA should suspend the use of the Innova lateral flow test immediately pending further investigation”.

He said there needed to be complete transparency over the way any test was evaluated and what the data showed.

“The problem is there is absolutely no transparency on the evaluation process from PHE and Porton Down,” Mr Evans said.

“The data that sits behind Innova's test, for instance, should be subject to independent scrutiny given the performance of the test has been questioned. Otherwise this could seriously undermine confidence in public testing and could be dangerous if these tests produce false negative results.”

He also questioned why the Government was “throwing public money” at Innova to move manufacturing to Wales when a company called British Biocell International had a "30-year history of producing lateral flow devices and could do the job producing the same number of tests of higher quality”.

“We should be supporting indigenous UK companies,” Mr Evans argued. “I find the whole thing so strange. For the UK Government to fund a private equity company based in the states buying tests out of China when it could have supported in a far more substantial way the UK is reprehensible."

Bedford-based diagnostics company Mologic, for instance, whose lateral flow test has surpassed WHO standards, had its test failed by PHE at Porton Down several times, for reasons its chief executive has said he could not understand.

Mologic was given nearly £1m by the Government last year to create a high-standard rapid lateral flow test but felt it had s

Could be good news!

AZ deeply involved in Lung Cancer, might be something for CIZ in future

Orpathys approved in China for lung cancer
ASTRAZENECA PLC
Released 07:00:05 23 June 2021

RNS Number : 8162C
AstraZeneca PLC
23 June 2021

23 June 2021 07:00 BST



Orpathys approved in China for patients

with lung cancer and MET gene alterations



First-in-class approval in China in this setting and first regulatory approval
for the oral, potent and highly selective MET tyrosine kinase inhibitor



AstraZeneca and HUTCHMED's Orpathys (savolitinib) has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy.



This approval follows a priority review designation by the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) and marks the first global regulatory approval for the oral, potent, and highly selective MET tyrosine kinase inhibitor (TKI).



More than a third of the world's lung cancer patients are in China and, among those with NSCLC, approximately 2-3% have tumours with MET exon 14 skipping alterations, a targetable mutation in the MET gene.1-3 This mutation is more common (13-22%) among patients with pulmonary sarcomatoid carcinoma (PSC), a rare and aggressive subtype of NSCLC usually resistant to chemotherapy.1,4



The approval by the NMPA was based on positive results from a single-arm Phase II trial conducted in China in patients with NSCLC with this mutation, including patients with the PSC subtype. Orpathys demonstrated robust anti-tumour activity based on an independent review of objective response rate (ORR) in the trial's primary endpoint and its disease control rate (DCR). Continued approval is contingent upon the successful completion of a confirmatory trial in this patient population.



Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: "This approval makes Orpathys the only targeted medicine approved for these biomarker-selected patients in China, and it adds another novel medicine to our already diverse lung cancer portfolio. We are proud that this first-ever regulatory approval of Orpathys is in China, where we have a long-standing commitment to improving patient outcomes and working with the right partners to achieve that goal. Alongside HUTCHMED, we look forward to the continued development of this medicine across a range of cancers where MET alterations and amplification are drivers of tumour growth and treatment resistance."



Christian Hogg, Chief Executive Officer, HUTCHMED, said: "It is with great pleasure that today we announce the first regulatory approval of Orpathys globally, HUTCHMED's third self-discovered oncology drug to be commercialized. Our collaboration with AstraZeneca in 2011 has been an important driver in the development of this novel targeted

Today's info from LSE board, so who is buying?

# of Trades 195
Vol Sold 818,360
Vol Bought 375,036
52 Week High 113.50
52 Week High Date 07-Oct-2020
52 Week Low 25.765
52 Week Low Date 17-Dec-2020

LB
Can you let us know where we can access this information
thanks
Chris

Cannot see anything posted after 8.08am

I would not trust a teetotaller, never mind a mathematician, lol

Why is everyone panicking, long term holders are still well in profit
We sat through a six month suspension and were only about 24 hours from a de-list before a new nomad was finally appointed, we got through that ( we actually had no choice, but hey ho)
The metals are still in the ground, the demand is increasing with climate change a centrepiece of global strategy along with the covid vaccine
If anyone sells now they may have to look back one day and think " i could have bought my Lambo , Porsche etc" But i bottled it!

From the Telegraph
https://www.telegraph.co.uk/business/2021/06/16/race-develop-lockdown-ending-covid-antibody-test-unravelled2/

If the emergency use authorisation for Innova expires on Tuesday how long will it take for stocks of whichever test is to replace it to reach local test centres and pharmacies etc ?
Unless there are large stocks of an, as yet unspecified replacement test, in warehouses what are PHE going to use, will ODX have been assisting Surescreen in manufacturing their approved test?
A lot of news must be about to be released if the testing programme is to stay on track and the Delta variant wave be contained.

I see that we are again highlighting our close proximity to Norilsk Nickel's plant

Eurasia Mining plc is a palladium, platinum, rhodium, iridium and gold producing company, operating the established West Kytlim Mine in the Urals, and also the operator of the Monchetundra Project comprising two predominantly palladium open pit deposits located 3km away from Severonickel, one of Norilsk Nickel's largest base metals and PGM processing facilities, near the town of Monchegorsk on the Kola Peninsula.

Looking interesting !
11-Jun-21 10:15:27 23.00 100,000 Buy* 22.00 23.00 23.00k O
11-Jun-21 10:14:35 23.00 15,752 Buy* 22.00 23.00 3,623 O
11-Jun-21 10:11:56 22.9999 43,461 Buy* 22.00 23.00 9,996 O
11-Jun-21 10:11:48 22.80 30,675 Buy* 22.00 23.00 6,994 O
11-Jun-21 10:11:28 22.80 250,000 Buy* 22.00 23.00 57.00k O
11-Jun-21 10:09:51 22.575 250,000 Buy* 22.00 22.50 56.44k O
11-Jun-21 10:09:04 22.45 500,000 Buy* 22.00 22.50 112.25k O

Last time this went up a good few % on the day, a few months ago now, there were loads of buys held over until the day after, this went on for a few days so difficult to gauge the level of buying.
Wonder if we will the same today and in the days to come?